Celecoxib for familial adenomatous polyposis

Onsenal is a new preparation of the COX-2 inhibitor celecoxib, indicated for use in familial adenomatous polyposis (FAP). Patients with this condition develop large numbers of intestinal polyps that overexpress COX-2. Left untreated, these polyps eventually progress to colorectal cancer.

In a randomised, controlled trial in 83 patients with FAP, treatment with celecoxib for 6 months reduced the number of polyps by a mean of 28% (compared with a mean reduction of 5% for placebo). Celecoxib has been studied only for up to 6 months in FAP, and has not been shown to reduce the risk of cancer or the need for surgery.

View Onsenal drug record

Further information: Pfizer

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases